Biogen Inc. (BIIB) Cash Flow Statement

The wide quarterly swings in OCF/NI, from 4.60 in Q2 2026 to -10.57 in Q4 2025, suggest that non-cash items and working capital changes heavily influence cash generation. In Q2 2026, net income of $97.5M was far below OCF of $448.9M, implying a large positive accrual adjustment, while Q4 2025's net loss of -$48.4M still produced $512.0M OCF, indicating that depreciation and amortization are significant. This inconsistency suggests that earnings quality is strained, and investors should monitor the sustainability of cash conversion as the product mix shifts.

The FCF margin trajectory is highly erratic, with a peak of 50.0% in Q3 2025 and a trough of 5.5% in Q2 2025, indicating that cash generation is not stable. The most recent quarter (Q2 2026) shows a margin of 17.9%, which is below the 28.1% seen in Q1 2026, suggesting a deceleration. This volatility may reflect timing of working capital and capex, but it also underscores the difficulty in forecasting Biogen's cash flows as it transitions from legacy MS to growth products.

Biogen's capital intensity is relatively low, with CapEx/Revenue averaging around 2-3%, but it spiked to 5.3% in Q2 2026 and Q4 2024. This suggests that the company is investing in manufacturing capacity or infrastructure, possibly to support new product launches. The low overall capital intensity implies that maintenance capex is not a major cash drain, but the variability warrants monitoring as the company integrates acquisitions and expands its portfolio.

The working capital changes are highly volatile, with large negative swings in Q2 2025 (-$789.6M) and Q1 2025 (-$333.5M), which likely reflect timing of collections and payables. In Q2 2026, working capital contributed +$127.9M to OCF, a positive swing from the prior quarter's -$127.9M. This volatility suggests that Biogen's cash flow is sensitive to working capital management, and investors should monitor the efficiency of receivables and inventory as the company scales new products.

The absence of shareholder returns in the form of dividends or buybacks over the past ten quarters is notable, especially given the company's fortress balance sheet. Instead, cash appears to be reserved for strategic acquisitions, as evidenced by the $1.1B net cash outflow for acquisitions in Q3 2024. This suggests that management is prioritizing portfolio transformation over returning capital to shareholders, which may be appropriate given the need to offset MS erosion, but it also implies that investors are not receiving direct cash returns.

The cumulative OCF of approximately $5.7B versus cumulative net income of $3.3B over the ten-quarter period suggests that Biogen's cash generation is robust, driven by significant non-cash charges like D&A and SBC. This divergence indicates that reported earnings understate the company's cash-generating ability, which may be a positive signal for valuation. However, the gap also highlights the impact of large working capital swings and one-time items, so investors should assess the sustainability of this cash flow advantage.